Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR AI

Date Submitted: Sep 24, 2022
Open Peer Review Period: Sep 24, 2022 - Nov 19, 2022
Date Accepted: Dec 28, 2022
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

Artificial Intelligence Algorithms in Health Care: Is the Current Food and Drug Administration Regulation Sufficient?

Mashar M, Chawla S, Chen F, Lubwama B, Patel K, Kelshiker MA, Bachtiger P, Peters NS

Artificial Intelligence Algorithms in Health Care: Is the Current Food and Drug Administration Regulation Sufficient?

JMIR AI 2023;2:e42940

DOI: 10.2196/42940

PMID: 38875544

PMCID: 11041443

Artificial Intelligence Algorithms in Health Care: Is the Current Food and Drug Administration Regulation Sufficient?

  • Meghavi Mashar; 
  • Shreya Chawla; 
  • Fangyue Chen; 
  • Baker Lubwama; 
  • Kyle Patel; 
  • Mihir A Kelshiker; 
  • Patrik Bachtiger; 
  • Nicholas S Peters

Given the growing use of machine learning (ML) technologies in health care, regulatory bodies face unique challenges in governing their clinical use. Under the regulatory framework of the Food and Drug Administration, approved ML algorithms are practically locked, preventing their adaptation in the ever-changing clinical environment, defeating the unique adaptive trait of ML technology in learning from real-world feedback. At the same time, regulations must enforce a strict level of patient safety to mitigate risk at a systemic level. Given that ML algorithms often support, or at times replace, the role of medical professionals, we have proposed a novel regulatory pathway analogous to the regulation of medical professionals, encompassing the life cycle of an algorithm from inception, development to clinical implementation, and continual clinical adaptation. We then discuss in-depth technical and nontechnical challenges to its implementation and offer potential solutions to unleash the full potential of ML technology in health care while ensuring quality, equity, and safety. References for this article were identified through searches of PubMed with the search terms “Artificial intelligence,” “Machine learning,” and “regulation” from June 25, 2017, until June 25, 2022. Articles were also identified through searches of the reference list of the articles. Only papers published in English were reviewed. The final reference list was generated based on originality and relevance to the broad scope of this paper.


 Citation

Please cite as:

Mashar M, Chawla S, Chen F, Lubwama B, Patel K, Kelshiker MA, Bachtiger P, Peters NS

Artificial Intelligence Algorithms in Health Care: Is the Current Food and Drug Administration Regulation Sufficient?

JMIR AI 2023;2:e42940

DOI: 10.2196/42940

PMID: 38875544

PMCID: 11041443

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.